Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae

James H. Jorgensen, Jana M. Swenson, Fred C. Tenover, Arthur Barry, Mary Jane Ferraro, Patrick R. Murray, L. Barth Reller

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

A six-laboratory collaborative study was conducted to develop MIC and zone diameter quality control limits and interpretive criteria for antimicrobial susceptibility testing of Streptococcus pneumoniae with azithromycin, clarithromycin, dirithromycin, and clindamycin. The MICs of all of the agents plus erythromycin for 302 clinical isolates of pneumococci that had been selected with an emphasis on resistant strains were determined by use of the National Committee for Clinical Laboratory Standards (NCCLS)- recommended broth microdilution procedure. The zone diameters of the isolates were also determined for the same agents except erythromycin by the NCCLS disk diffusion test procedure. Repeated testing of S. pneumoniae ATCC 49619 with different sources and lots of media and disks allowed development of 52 and zone diameter quality control ranges for these agents. Interpretive criteria for the MIC of azithromycin were established and were as follows: susceptible, ≤0.5 μg/ml; intermediate, 1 μg/ml; and resistant, ≤2 μg/ml. The interpretive criteria advocated for the MICs of clarithromycin and clindamycin were as follows: susceptible, ≤0.25 μg/ml; intermediate, 0.5 μg/ml; and resistant, ≤1 μg/ml. Comparison of MICs and disk diffusion zone diameters led to the development of interpretive criteria for the zone diameters for azithromycin, clarithromycin, and clindamycin that correlated well with these MIC breakpoints. Testing of this organism collection also led to the reestablishment of the erythromycin MIC breakpoints as being identical to those of clarithromycin, which resulted in equivalent cross-susceptibility and cross-resistance for the three macrolides that are currently marketed in the United States. Thus, the susceptibility of pneumococci to azithromycin and clarithromycin can be predicted accurately by testing only erythromycin in clinical laboratories. This recommendation, as well as the interpretive and quality control criteria that are described, have been accepted by NCCLS and are included in the latest NCCLS susceptibility testing guidelines.

Original languageEnglish (US)
Pages (from-to)2679-2684
Number of pages6
JournalJournal of clinical microbiology
Volume34
Issue number11
DOIs
StatePublished - Nov 1996

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae'. Together they form a unique fingerprint.

Cite this